Both trials are testing Xtandi in men with hormone-sensitive prostate cancer
Researchers examined data on 36,375 adults with no history of heart disease or diabetes and a low 10-year risk for events like heart attacks or strokes
The study was not designed to determine whether or how exercise or physical fitness may directly influence glaucoma risk
27,195 individuals aged 18 years and older in the Swedish National Diabetes Register who had been diagnosed with type 1 diabetes were studied
Dr Harleen Kaur,Senior Scientist, AstraZeneca USA, through her research paper, talks about collaborative approaches which can make huge difference in treating cancer
Research published in Nature Medicine describes collaborative effort to reduce off-target CRISPR-Cas9 genome editing, removing barriers for human therapeutic applications
According to Eisai, the company had already contacted various regulators and plans to pursue accelerated approvals
First single-dose medicine to prevent the relapse of P. vivax malaria marks a major contribution towards malaria eradication efforts
Verseon’s drug candidates target cancer cells by inhibiting the protein tubulin, which leads to cell cycle arrest
Helperby Therapeutics presented data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) announcing Phase I results on tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both...
Lupin’s biosimilar plans are reaching a crucial inflexion point, with recent positive global Phase III results of its etanercept biosimilar for rheumatoid arthritis. As research on other biosimilars in...
The pigments can regulate a key enzyme in cancer cells
Promising anti-fungal and anti-inflammatory properties for vaginal candidiasis therapy
MK Chattopadhyay, Retired Senior Principal Scientist, Centre for Cellular and Molecular Biology (CSIR), talks about the urgent need for new antibiotics which will be effective against resistant organisms
The study was a multinational randomised double-blind controlled trial of 52 weeks duration which included more than 500 patients with rheumatoid arthritis in 11 countries
Cancer cells are killed more effectively and selectively with a new approach, using a substance found in stinging nettles and ants, informs a study
India has already become the world capital of diabetes and heart diseases, and is set to acquire the same dubious distinction in other chronic diseases, too. Considering the need...
By Biten Kathrani, Director R&D, Asia Pacific, Boston Scientific outlines the trends which will drive progress in the R&D industry and examines whether the sector...
Biocon has recently launched a biosimilar in the Indian market. Suresh Subramanian, Sr Vice President & Head Branded Formulations, Biocon, gives more details about the product and their plans...
37 per cent of patients in a closely watched clinical trial who received Tecentriq, Avastin and chemotherapy reached the one-year mark without their cancer progressing
The review covers combination therapy for the adjuvant treatment of patients with stage III melanoma
The ZPIV vaccine, made from inactivated Zika virus particles, was developed by US Army researchers, who in July 2016 had agreed to give Sanofi an exclusive license to complete...
The company said it plans to price the drug at $676 per prescription, which it described as ‘at parity’ to current market-leading drugs in the same class
A study released in March of more than 27,500 patients showed that Repatha cut the risk of heart attacks by 27 per cent and stroke by 21 per cent...
Opdivo, or nivolumab is a PD-1 inhibitor, designed to help the body’s own immune system fend off cancer by blocking a protein called PD-1
Cancer drugs that cause tumours to shrink are considered likely to confer a meaningful clinical benefit, such as survival
The new study allows prevention measures to be targeted at those individuals most at risk of developing IE